Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

Agreement expands Cardio Diagnostics' global footprint and supports improved detection and management of coronary heart disease in India.

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD ™, an ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

On Average, 41% More Sensitive Than Current Tests for Predicting Future Heart Disease in Women CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its ...

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs partner to bring PrecisionCHD test to India, aiming to address high heart ...

Cardio Diagnostics, Aimil & Dr Lal PathLabs partner to introduce PrecisionCHD test in India: Our Bureau, Mumbai Friday, January 9, 2026, 11:15 Hrs [IST] Cardio Diagnostics Holding ...

Shares of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) climbed about 9.3% in premarket trading on Wednesday after the company unveiled plans to expand into India, marking its first move beyond the U.

We’ve done some strength and flexibility benchmarks, so I suppose it’s only fair we do one for cardio. Your Fitbit or Apple Watch may give you some numbers, like a VO2max, but I prefer a simpler test.